Phaseline

Companies › Tianjin Hemay Pharmaceutical

Tianjin Hemay Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hemay022–Phase 3Breast Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06313983Hemay022Phase 3Breast CancerOncologyDec 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.